Q2 2023 Pharma Services Update
Despite an uncertain macroeconomic environment, recessionary fears, and the impact of tightening credit markets, M&A activity in pharma services displayed strong resiliency in Q2-23, fueled by platform investments and dozens of add-on acquisitions. Investors remain attracted to the long-term tailwinds driving growth across outsourced pharma services including R&D funding, reducing costs, technological advancements, and access to value-added specialty services. Certain therapeutic areas, oncology and CNS diseases for example, will likely remain popular due to a robust pipeline of R&D activity.
Provident expects M&A activity to rebound in the second half of 2023 as companies look to fill the potential growth gap from the $100B in patents set to expire by 2030.
To print and download the full Pharma Services Update report, please click below…
